References
- Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome – positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878
- Breccia M, Carmosino I, Russo E, Morano S G, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005; 74: 121–123
- Shimazaki C, Ochiai N, Uchida R, Fuchida S I, Okano A, Ashihara E, et al. Intramuscular edema as a complication of treatment with imatinib. Leukemia 2003; 17: 804–805
- Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet 2003; 361: 1954–1956
- Heuchel R, Berg A, Tallquist M, Ahlen K, Reed R K, Rubin K, et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signalling. Proc Natl Acad Sci 1999; 96: 11410–11415
- Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201–206